Newsquawk Logo

US PRE-MARKET MOVERS: ACLX, VRE, DPZ, GOOGL, NVDA, NFLX, GIS, VFC, NVO

The pre-market movers indicate a mixed sentiment in the US equity landscape, with significant movers highlighting key acquisition news and some notable downgrades.

Newsquawk StaffPublished On the live feed at — 3 more headlines followed before this page went public
Newsquawk headlinesUTC

Paramount's Skydance (PSKY) revised offer for Warner Bros Discovery (WBD) will likely come in at USD 32/shr, Variety reports

Newsquawk Daily US Conference Calendar - 23rd February 2026: BA, PFE

US PRE-MARKET MOVERS: ACLX, VRE, DPZ, GOOGL, NVDA, NFLX, GIS, VFC, NVO

UK Government Spokesperson says nothing is off the table in response to US tariffs; is discussing tariffs with the US administration at all levels; talks will continue

Dominion Energy Inc (D) Q4 2025 (USD): EPS 0.68 (exp. 0.67), Revenue 4.09bln (exp. 3.65bln). FY26 EPS view 3.45-3.69 (exp. 3.60)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.

ES -0.5% NQ -0.6% RTY -0.8%

  • ACLX +79%: To be acquired by GILD for $7.8bln or $115/shr; note, ACLX closed Fri. at 64.11
  • VRE +12.5%: To be acquired by Affinius for $3.4bln or $19/shr; note, VRE closed Fri. at 16.77
  • DPZ +5.5%: Rev. beat w/ 15% increase in Q div.
  • GOOGL +0.4%: Upgraded at Wells Fargo
  • NVDA -0.3%: Cos. laptop chips are set to launch this year in products from DELL & LNVGY, marking a return to the consumer PC mark
  • NFLX -0.7%: Trump said Netflix should fire Susan Rice “immediately” or “pay the consequences”
  • GIS -0.8%: Downgraded at BofA
  • VFC -3.4%: Downgraded at JPM
  • NVO -14%: CagriSema 2.4 did not meet the primary endpoint of showing non-inferiority on weight loss vs tirzepatide 15mg at 84 weeks
Context

ACLX and VRE are substantially up due to acquisition premiums, while NVO's sharp decline reflects disappointing clinical trial results, potentially impacting market confidence in biotech stocks. This environment suggests traders should be cautious with positions in sectors affected by these developments, particularly biotech and consumer stocks.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.